Allink Biotherapeutics
Shanghai
About Allink Biotherapeutics
Allink Biotherapeutics is a biopharmaceutical company that develops multi-specific antibodies for oncology and immunology treatment. The company establishes a proprietary masked T-cell engager (TCE) platform to evolve the application of TCEs for solid tumors. In the immunology space, AllinkBio is advancing a portfolio of first-in-class bi- and multi-specific antibody drug candidates. Anchored in rational biology design, these programs aim to deliver next-generation solutions for patient populations underserved by current standards of care.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $89.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2025)
- Website: en.allinkbio.com
Industries & Categories
Biopharma, Biotechnology, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/allink-biotherapeutics-44782 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.